Use of GLP-2 in a combination treatment for bone-related disorders
First Claim
Patent Images
1. A method of treatment of a patient having an undesirably low bone mass or an undesirably high rate of bone resorption or an undesirably low rate of bone formation, which method comprises administering to the patient a therapeutically effective amount of each of:
- a) a first active component which promotes bone formation and promotes bone resorption; and
b) a second active component which is a GLP-2, or a variant, an analogue, or derivative, or mimic of GLP-2 having the ability to bind and activate a GLP-2 receptor, or is a GLP-2 receptor agonist.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods of treatment of patients having an undesirably low bone mass or an undesirably high rate of bone resorption or an undesirably low rate of bone formation, which method comprises administering to the patient a therapeutically effective amount of each of:
- a) a first active component which promotes bone formation and promotes bone resorption, e.g. PTH; and
- b) a second active component which is a GLP-2, or a variant, an analogue, or derivative, or mimic of GLP-2 having the ability to bind and activate a GLP-2 receptor, or is a GLP-2 receptor agonist.
27 Citations
24 Claims
-
1. A method of treatment of a patient having an undesirably low bone mass or an undesirably high rate of bone resorption or an undesirably low rate of bone formation, which method comprises administering to the patient a therapeutically effective amount of each of:
-
a) a first active component which promotes bone formation and promotes bone resorption; and b) a second active component which is a GLP-2, or a variant, an analogue, or derivative, or mimic of GLP-2 having the ability to bind and activate a GLP-2 receptor, or is a GLP-2 receptor agonist. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24)
-
-
19. A method of treating hypercalcemia by therapy or by prophylaxis comprising administering to a patient in need thereof a therapeutically effective amount of a GLP-2, an analogue or derivative or mimic of GLP-2 having the ability to bind and activate a GLP-2 receptor, or is a GLP-2 receptor agonist.
Specification